The term ‘carcinoid’ entered medical literature over 100 years ago to describe a peculiar intestinal epithelial neoplasm. Since then, a large body of literature has expanded the concept of carcinoid, later replaced by the term ‘NeuroEndocrine Tumor’ (NET), defining a wide spectrum of peculiar tumors, potentially affecting all organs and tissues, originating from neuroendocrine cells, sharing but, at the same time, keeping pathognomonic pathological, radiological and clinical features.

This book provides an authoritative overview of the epidemiological, clinical, genetic, molecular and pathological characteristics of NETs and highlights the most relevant controversial issues in the classification, diagnosis and therapy. Furthermore, the new frontiers in the field of medical therapies are presented, through a multidisciplinary and translational approach. Considering the fact that NETs have been recently demonstrated less rare as considered so far, Neuroendocrine Tumors: A Multidisciplinary Approach is a must-read for endocrinologists, gastroenterologists, endocrine surgeons, as well as pathologists, nuclear medicine physicians and radiologists focused on NET.

Contents
Preface: Papotti, M.; de Herder, W.W.; Ghigo, E.; Guaraldi, F.
• Epidemiology of Neuroendocrine Tumors: Fraenkeli, M.; Faggiano, A.; Vali, G.D.
• Biochemical Testing in Patients with Neuroendocrine Tumors: Granberg, D.
• Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms: Boutsios, G.; Kaltzas, G.
• Radiological Imaging: Computed Tomography, Magnetic Resonance Imaging and Ultrasound: Sundin, A.; Wilts, M.; Rockall, A.
• Nuclear Medicine Imaging of Neuroendocrine Tumors: Brabander, T.; Vekkeboom, D.J.; Feelders, R.A.; Brouwers, A.H.; Teunissen, J.J.M.
• Endoscopic and Endoscopic Ultrasound in Assessing and Managing Neuroendocrine Neoplasms: O’Toole, D.; Palazzo, L.
• Pathology: Classification and Immunoprofile: Blank, A.; Schmitt, A.; Perren, A.
• Genetics and Epigenetics of Pancreatic Neuroendocrine Tumors and Pulmonary Carcinoids: Drejerink, K.M.A.; Derks, J.L.; Cataldo, I.; Scapar, A.; Valk, G.D.; Speel, E.J.M.
• Pancreatic Surgery: Maurizi, A.; Partelli, S.; Falconi, M.
• Transplantation and Debunking Procedures for Neuroendocrine Tumors: Frilling, A.; Al-Nahhas, A.; Clift, A.K.
• A 25-Year Experience of Gastroenteropancreatic Neuroendocrine Tumors and Somatostatin (Congeners) Analog: From Symptom Control to Antineoplastic Therapy: O’Dorisio, T.M.; Anthony, L.B.
• Medical Therapy of Pulmonary Neuroendocrine Neoplasms: Targeted, Symptomatic and Chemotherapy: Follola, P.
• Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Bodei, L.; Kidd, M.; Prasad, V.; Modlin, I.M.
• Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors: Hoffland, L.J.; Vandamme, T.; Albertelli, M.; Ferone, D.
• The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: Strosberg, J.; Goldman, J.; Costa, F.; Pavel, M.
• Other Novel Therapies: Biomarkers, microRNAs and DNA Methylation, Epigenetics, Immunotherapy and Virotherapy: Giandomenico, V.; Thirwell, C.; Essand, M.

The easiest way to order: www.karger.com/fhore
Oncology

International Journal of Cancer Research and Treatment

Founded 1948 as 'Oncologia' by H.R. Schinz

Editor-in-Chief
M. Markman, Philadelphia, Pa.

Associate Editor
P. Dufour, Strasbourg

Regional Editor Japan
O. Hino, Tokyo

Editorial Board
A.B. Benson, Chicago, Ill.
A. Chang, Singapore
A.L. Cheng, Taipei
J.F. Cleary, Madison, Wis.
M. Dietel, Berlin
M.S. Ernstoff, Cleveland, Ohio
M.G. Fakih, Duarte, Calif.
J.J. Grau, Barcelona
H. Gronemeyer, Illkirch
C.S. Johnson, Buffalo, N.Y.
M.J. Kelley, Durham, N.C.
L. Kumar, New Delhi
P.J. Loehrer, Indianapolis, Ind.
J.R. Marshall, Buffalo, N.Y.
S. Monfardini, Milan
R. Nagler, Haifa
R. Ohno, Nagoya
B. Pestalozzi, Zurich
H.M. Pinedo, Amsterdam
E.A. Repasky, Buffalo, N.Y.
A. Semczuk, Lublin
E.F. Smit, Amsterdam
C.N. Sternberg, Rome
R. Stupp, Zurich
M.S. Tallman, New York, N.Y.
S. Tanaka, Hiroshima
M. Tian, Houston, Tex.
D.L. Trump, Buffalo, N.Y.
T. Wiegel, Ulm
W. Yasui, Hiroshima
H. Zhang, Hangzhou City
Guidelines for Authors

Submission

Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to Oncology online and must be accompanied by a cover letter signed by the submitting/corresponding author on behalf of all co-authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/ocl, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Dr. M. Markman
S. Karger AG
Editorial Office ‘Oncology’
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1359
Fax +41 61 306 1434
E-Mail ocl@karger.com

Mailing address for courier deliveries only:
Allschwilerstr. 10
CH–4055 Basel (Switzerland)

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Oncology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Authors originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Accordingly, the subject’s informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject’s identity is to be avoided.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Categories of Manuscripts

Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

Clinical Studies and Clinical Translational Research Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).

Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.

Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a ‘positive result’, but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.

Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.

Editorials are commentaries on current topics or on papers published elsewhere in the issue. Word count limit is 1,500 and 10 references are allowed. They are usually invited by the Editor.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in oncology are also welcome. The length should not exceed 300 words.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).
Oncology

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum inter- leukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. peer-reviewed) or post-prints (i.e. accepted manuscript after peer review but before production) on their institutional or personal websites. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogeten Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 7 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
Submit an abstract to participate fully in the conference via a poster presentation and possible selection for a short talk. Abstract and discounted registration deadlines are three and two months, respectively, before meetings begin. For full program and deadline details, visit www.keystonesymposia.org/cancer.
ICACT 2016
27th International Congress on Anti-Cancer Treatment

ÉTOILE SAINT-HONORÉ
21-23-25 rue Balzac - 75008 Paris

2nd - 4th February 2016

A World Leading Educational meeting

70 Speakers
22 Concurrent Sessions
20 Topics

For further information, kindly visit www.icact.com or send us email via infos@im-events.com.
We look forward to your participation in the 27th International Congress on Anti-Cancer Treatment
3rd Immunotherapy of Cancer Conference

21 – 23 MARCH 2016 | MUNICH, GERMANY

THE LEADING EUROPEAN CONFERENCE PROVIDING A GLOBAL PLATFORM FOR IMMUNO-ONCOLOGY

Conference objectives:

- To bring together preclinical and clinical scientists, academia and clinical investigators to address unique challenges of immunotherapy
- To provide opportunities to present scientific data in relation to early clinical trials
- To encourage new approaches for translation research and biomarkers
- To translate molecular targets into effective cancer therapy
- To bring together a multi-stakeholder audience and foster productive collaboration among investigators

View the Advance Programme and register!

Further information: www.itoc-conference.eu
Onco Update Europe 2016

2nd European Update Congress in Oncology
Budapest, 22–23 April 2016

- Complete medical field in two days
- Cutting-edge study results
- Ensured practical relevance

Submit an ePoster
Save 200 €

Scientific board
Florian Lordick, Germany
Silke Gillessen, Switzerland
Giampaolo Tortora, Italy
Marcel Verheij, Netherlands

Registration and further information
www.onco-update-europe.eu

Cancer Biology and Targeted Treatment
Giampaolo Tortora, Italy

Lymphoma
Peter Johnson, UK

Myeloid Malignancies
Gert Ossenkoppele, Netherlands

Melanoma
Axel Hauschild, Germany

Gynecological Cancer
Antonio Gonzalez, Spain

Radiation Oncology
Marcel Verheij, Netherlands

Prostate Cancer
Silke Gillessen, Switzerland

Colorectal Cancer
Alberto Sobrero, Italy

Genito-urinary Tract Cancer
Cora Sternberg, Italy

Sarcoma, including GIST
Ian Judson, UK

Upper Gastrointestinal Tract Cancer
Florian Lordick, Germany

Lung Cancer
Jan van Meerbeeck, Belgium

Hot Topic: Supportive & Palliative Care Therapy
Jørn Herrstedt, Denmark

Breast Cancer
Michael Gnant, Austria

Registration and further information
www.onco-update-europe.eu
It is with great excitement and anticipation that we invite you to participate in the next Advances in Neuroblastoma Research Congress to be held in Cairns, Australia in 2016, on the Great Barrier Reef.

This meeting will provide a key opportunity for research scientists, clinicians, early career fellows, nurses and other allied health care workers and parents to be updated on the latest basic, translational and clinical research developments in the field of childhood neuroblastoma.

ABSTRACTS due by 1 February 2016. Abstracts can only be submitted by Full Members of the ANRA.

Membership closes December 31st: 2015!
For more information, visit www.anrmeeting.org.

ANR 2016 will run in conjunction with
ANZCHOG: 23rd - 25th June
(Australian & New Zealand Children's Haematology/Oncology Group)
SIOPEN: 24th - 25th June
(International Society of Paediatric Oncology Europe Neuroblastoma)
18TH WORLD CONGRESS ON
Gastrointestinal CANCER

29 JUNE - 2 JULY 2016
BARCELONA, SPAIN

Chairs
Mario Dicato, MD
Luxembourg Medical Center
Luxembourg, Luxembourg

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg
Leuven, Belgium

Vice Chair
Josep Tabernero, MD, PhD
Vall d’Hebron University Hospital
Barcelona, Spain

REGISTER ONLINE AT WORLDGICANCER.COM

IMPORTANT DATES
Early Registration Deadline 7 April 2016
Discounted Registration Deadline 16 June 2016
Abstract Submission Deadline 7 March 2016
24th Biennial Congress of the
European Association for Cancer Research
From Basic Research to Precision Medicine

EACR 24

9 – 12 July 2016 | Manchester, UK

This Congress will offer:

- **Innovation**: pushing the agenda to make precision medicine a reality
- **Focus**: participants can create a tailor-made programme from the 3 parallel tracks covering 18 priority areas
- **Breadth**: the EACR Congress is Europe’s largest dedicated conference on basic and translational research
- **Sharing**: poster sessions and proffered papers to allow researchers at all levels to share their results and discoveries
- **Networking**: excellent opportunities to meet new contacts and develop new collaborations

Join us in Manchester and be inspired by colleagues from around the world.

Further information: www.ecco-org.eu/EACR24
#EACR24
Chronic Liver Diseases and Liver Cancer: An Update in 2015

Editors
Masatoshi Kudo
Okio Hino
Soo-Ryang Kim
Hyo-Suk Lee
Kwang Hyub Han
Young-Hwa Chung

Contents

Preface

Chronic Liver Diseases and Liver Cancer: An Update in 2015: Kudo, M.

Original Articles


Review Articles

• Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi’s Subclassification (Kinki Criteria): Kudo, M.; Arizumi, T.; Ueshima, K.; Sakurai, T.; Kitano, M.; Nishida, N.

• Cone-Beam CT Angiography for Hepatocellular Carcinoma: Current Status: Minami, Y.; Murakami, T.; Kitano, M.; Sakurai, T.; Nishida, N.; Kudo, M.


• Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma: Nishida, N.; Kitano, M.; Sakurai, T.; Kudo, M.

• Challenges of Clinical Research on Hepatocellular Carcinoma: Kudo, M.; Kitano, M.; Sakurai, T.; Nishida, N.

Author Index / Subject Index

The easiest way to order: www.karger.com/ddi
Pathobiology offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, Pathobiology features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.

Pathobiology
Founded: 1938
Category: Basic and Clinical Research
Field of Interest: Pathology
Listed in bibliographic services, including Journal Citation Reports, PubMed/MEDLINE, Biological Abstracts, Embase
2016: Volume 83
6 issues per volume
Language: English
ISSN 1015–2008
e-ISSN 1423–0291
Impact Factor: 2.480

More information at www.karger.com/pat

Selected contributions
- Biobanking Trends, Challenges, and Opportunities: Mackenzie, F., (Glasgow)
- The Role of Diagnostic Tissue in Research: Cheung, C.C.; Torlakovic, E.E.; Porvivi, A., (Toronto, Ont.)
- DNA Damage Response-Related Proteins in Gastric Cancer: ATM, Chk2, and p53 Expression and Their Prognostic Value: Lee, H.E.; Han, N.; Kim, M.A. (Seoul); Lee, H.S. (Seoul/Seongnam); Yang, H.-K.; Lee, B.L.; Kim, W.H., (Seoul)
- Skeletal Metastatic Carcinomas from the Roman Period (1st to 5th Century AD) in Hungary: Merczi, M., (Esztergom); Marcisz, A., (Sáreged);
  Bernert, Z.; Józsa, L.; Buczko, K.; Lassányi, G., (Budapest); Kelemen, M.H. (Esztergom); Zádori, P.; Vandulek, C.; Biró, G., (Kaposvár/Seoul); Hajdú, T., (Budapest); Molnár, E., (Sáreged)
- Assessment of Chimerism in Epithelial Cancers in Transplanted Patients: Leboeuf, C.; Ratajczak, P.; Vérine, J.; Elbouchtaoui, M.; Plassa, F.; Legrès, L.; Ferreira, I.; Sandid, W.; Varna, M.; Bousquet, G., (Paris); Verneuil, L., (Paris/Caen);
  Janin, A., (Paris)
- Critical Role of the GM-CSF Signaling Pathway in Macrophage Pro-Repair Activities: Bernasconi, E.; D’Angelo, F.; Michetti, P.; Velin, D., (Lausanne)
- Absence of Microsatellite Instability In Soft Tissue Sarcomas: Campanella, N.C.; Penna, V.; Ribeiro, G.; Abraham-Machado, L.F.; Scapulatempo-Neto, C., (Barretos); Reis, R.M., (Barretos/Braga/Guimarães)
Clinical Studies

305 Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively

311 Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer
Lee, S.Y.; Kim, C.H.; Kim, Y.J.; Kim, H.R. (Gwangju)

319 Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

332 Complications after Radiofrequency Ablation of 233 Hepatic Tumors
Fonseca, A.Z.; Saad, W.A.; Ribeiro Jr., M.A. (São Paulo)

337 Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis
Lee, H.J.; Kim, J.Y.; Song, I.H.; Park, I.A.; Yu, J.H.; Gong, G. (Seoul)

Clinical Translational Research

345 Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer

351 Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer
Yoon, S.; Kim, J.G.; Seo, A.N.; Park, S.Y.; Kim, H.J.; Park, J.S.; Choi, G.S. (Daegu); Jeong, J.Y. (Gumi); Jun, D.Y.; Yoon, G.S.; Kang, B.W. (Daegu)

Short Communication

360 Diagnostic Utility of Unbiased Circulating Tumour Cell Capture through Negative Depletion of Peripheral Blood Cells

365 Acknowledgement to the Reviewers

after

366 Contents Vol. 89, 2015